Zinc valerate | 556-38-7

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Zinc valerate
• 英文别名: zinc;pentanoate
• CAS: 556-38-7
• 化学式: C10H18O4Zn
• 分子量: 267.6
• InChiKey: BUDAIZWUWHWZPQ-UHFFFAOYSA-L

物化性质

• 溶解度：
  微溶于H2O；与酸溶液发生反应；溶于乙醇
• LogP：
  1.309 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.15
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  80.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] PHARMACEUTICAL COMPOSITIONS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES
  申请人：GENZYME CORP

  公开号：WO2009154747A1

  公开（公告）日：2009-12-23

  This invention relates to crosslinked amine-containing polymers for binding compounds or ions, and more specifically relates to pharmaceutically acceptable compositions for binding compounds or ions that include crosslinked amine-containing polymers. The pharmaceutically acceptable composition includes, for example, crosslinked polyamine particles, or pharmaceutically acceptable salts thereof, having a particle size distribution wherein greater than 10 vol.% of the particles have a particle size greater than 500 μm.

  这项发明涉及交联胺含有聚合物用于结合化合物或离子，更具体地涉及用于结合化合物或离子的药用可接受组合物，其中包括交联胺含有聚合物。药用可接受组合物包括例如交联聚胺颗粒或其药用可接受盐，具有粒径分布，其中大于10体积%的颗粒具有大于500μm的粒径。
• Mixtures composed of monocarboxy-functionalized dialkylphosphinic acid salts, their use und a process for their preparation
  申请人：Maas Wiebke

  公开号：US20070213563A1

  公开（公告）日：2007-09-13

  The invention relates to mixtures composed of monocarboxy-functionalized dialkylphosphinic salts and of further components, which comprise A) from 98 to 100% by weight of monocarboxy-functionalized dialkylphosphinic salts of the formula (I) in which X and Y are different, where X is Ca, Al, or Zn, and Y is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, phenyl, 2-hydroxyethyl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 4-hydroxybutyl, 3-hydroxybutyl, 2-hydroxybutyl, and/or 6-hydroxyhexyl, allyl and/or glycerol; or X and Y are different and are Mg, Sb, Sn, Ge, Ti, Fe, Zr, Ce, Bi, Sr, Mn, Cu, Ni, Li, Na, K, H, and/or a protonated nitrogen base; or X and Y are identical or different and each is then Ca, Al, or Zn; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are identical or different and, independently of one another, are H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, and/or phenyl, and B) from 0 to 2% by weight of halogens, where the entirety of the components always amounts to 100% by weight; and to a process for their preparation and to their use.

  该发明涉及由单羧基功能化二烷基膦盐和进一步组分组成的混合物，其中包括A）98至100重量％的单羧基功能化二烷基膦盐，其化学式为（I），其中X和Y不同，其中X为Ca、Al或Zn，Y为甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、苯基、2-羟乙基、2,3-二羟基丙基、2-羟基丙基、3-羟基丙基、4-羟基丁基、3-羟基丁基、2-羟基丁基和/或6-羟基己基、烯丙基和/或甘油；或X和Y不同且为Mg、Sb、Sn、Ge、Ti、Fe、Zr、Ce、Bi、Sr、Mn、Cu、Ni、Li、Na、K、H和/或质子化氮碱；或X和Y相同或不同，每个为Ca、Al或Zn；R1、R2、R3、R4、R5、R6和R7相同或不同，互相独立，为H、甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基和/或苯基；B）0至2重量％的卤素，其中所有组分的总量始终为100重量％；以及其制备方法和用途。
• [EN] ZINC COMPOUND AND CYCLODEXTRINE FOR TREATMENT OF GASTRIC DISORDERS<br/>[FR] COMPOSE DE ZINC ET CYCLODEXTRINE UTILISES DANS LE TRAITEMENT DES TROUBLES GASTRIQUES
  申请人：BELLARA MEDICAL PRODUCTS LIMITED

  公开号：WO1995025513A1

  公开（公告）日：1995-09-28

  (EN) A pharmaceutical composition and a method for the treatment of gastric disorders and $i(Helicobacter pylori) in the stomach or duodenum comprising a zinc compound and a cyclodextrin or cyclodextrin derivative for instance selected from $g(a)-cyclodextrin, $g(b)-cyclodextrin or $g(g)-cyclodextrin. The pharmaceutical composition may also include a pharmaceutically acceptable acidic compound such as a carboxylic acid.(FR) L'invention se rapporte à une composition pharmaceutique et à un procédé destinés au traitement des troubles gastriques et dus à la présence d'$i(Hélicobacter pylori) dans l'estomac ou le duodénum, ladite composition comprenant un composé de zinc et une cyclodextrine ou un dérivé de cyclodextrine, par exemple, la cyclodextrine étant sélectionnée parmi la cyclodextrine $g(a), la cyclodextrine $g(b) ou la cyclodextrine $g(g). La composition pharmaceutique peut également comprendre un composé acide pharmaceutiquement acceptable, tel qu'un acide carboxylique.

  一种药物组合物和治疗胃部疾病和胃或十二指肠中的幽门螺杆菌的方法，包括一种锌化合物和一种环糊精或环糊精衍生物，例如选择自α-环糊精、β-环糊精或γ-环糊精。该药物组合物还可以包括一种药学上可接受的酸性化合物，例如羧酸。
• Process for preparation of dialkylphosphinic salts
  申请人：Bauer Harald

  公开号：US20050137418A1

  公开（公告）日：2005-06-23

  The invention relates to a process for preparation of salts of dialkylphosphinic acids, which comprises a) reacting hypophosphorous acid and/or its salts with olefins in the presence of a free-radical initiator to give dialkylphosphinic acids and/or their alkali metal salts, in a solvent system, and b) reacting the dialkylphosphinic acids and/or alkali metal dialkylphosphinates obtained in a) with compounds of the metals Mg, Ca, Al, Zn, Ti, Sn, Zr, and/or Fe to give the dialkylphosphinic salts of these metals. The invention also relates to the use of the metal dialkylphosphinic salts obtained by the inventive process, in particular for preparation of flame retardants.

  本发明涉及一种制备二烷基膦酸盐的过程，包括a)在溶剂体系中，在自由基引发剂的存在下，将亚磷酸及/或其盐与烯烃反应，得到二烷基膦酸及/或其碱金属盐；b)将a)步骤得到的二烷基膦酸及/或碱金属二烷基膦酸盐与Mg、Ca、Al、Zn、Ti、Sn、Zr和/或Fe的化合物反应，得到这些金属的二烷基膦酸盐。本发明还涉及使用通过本发明的方法获得的金属二烷基膦酸盐，特别是用于制备阻燃剂。
• Use Of Manganese Oxalates As Bleach Catalysts
  申请人：Reinhardt Gerd

  公开号：US20110166055A1

  公开（公告）日：2011-07-07

  The invention relates to the use of manganese oxalates in detergents and cleaning agents, in particular in cleaning agents containing peroxy compounds for hard surfaces.

  本发明涉及在洗涤剂和清洁剂中使用草酸锰，特别是在含有过氧化物化合物的硬表面清洁剂中使用。